Start triage first, then route to emergency care.
Need urgent help? Start triage first, then route to emergency care.
Roxee Medication Guide
Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.
Veterinary professional?
These are the reference facts Roxee uses on browse cards and quick facts.
Sponsor, product, and application records imported from Animal Drugs @ FDA.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Dog
Manufacturer: Multiple FDA labelers
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks. Species commonly shown: Dog.
Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.
Oral
Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.
Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed.
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continueStart here first for the safest next-step summary before the deeper medication detail.
Used for:
For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
When to call the vet:
What to tell or ask your vet today:
A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.
Roxee has limited cited overview evidence for Trilostane; use the official documents and your veterinarian's instructions for product-specific decisions.
32 tracked reaction signals; 32 reported cases; 20 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.
Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.
Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.
Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.
Elevated total bilirubin (1 reports), Elevated serum alkaline phosphatase (1 reports), Ear infection NOS (1 reports), Drug prescribing error (1 reports), Dilated renal pelvis (1 reports)
Digestive (4), Behavior (1), Other (27)
Dog (26 reports), Cat (6 reports)
['Terrier (unspecified)', 'Dog (unknown)'] (2), Dachshund - Miniature (1), ['Chihuahua', 'Dog (unknown)'] (1), Bulldog - French (1). These are report metadata, not proof that a breed is at higher risk.
Verify whether Trilostane fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.
Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.
Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches, Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors, Elevated total bilirubin, Elevated serum alkaline phosphatase, Ear infection NOS
Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.
Review status / Updated / Sources
Review status: Clinical reviewer not listed
Updated: February 12, 2026, 7:40 PM UTC
Side effects to monitor:
Most reported reactions:
Emergency warning signs:
Source-backed clinical checkpoints for quick review.
Official label facts first, then secondary summaries. Marketing content is separated below.
Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.
Received 2026-01-20 · MSK · MSK
Received 2025-12-16 · MSK · MSK
Received 2025-12-16 · MSK · MSK
Received 2025-12-16 · MSK · MSK
Tap or hover a reaction to see what it means in plain language.
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 |
Species coverage: Dog (26) Cat (6)
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Digestive | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Digestive | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Digestive | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Behavior | Cat | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Digestive | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 |
Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.
The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.
Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.
Full source previews and metadata remain in the veterinary/professional layer.
Official label / PI · Labeling
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
FOI · FOI
FOI · FOI
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
Quick facts and links to official labeling and safety signals.
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 17033-105-30 | 17033 | - | |
| 17033-110-30 | 17033 | - | |
| 17033-111-30 | 17033 | - | |
| 17033-112-30 | 17033 | - | |
| 17033-130-30 | 17033 | - | |
| 17033-160-30 | 17033 | - | |
| 58597-7038-6 | 58597 | - | |
| 62157-361-01 | 62157 | - | |
| 62157-401-01 | 62157 | - | |
| 62157-556-01 | 62157 | - | |
| 62157-557-01 | 62157 | - | |
| 62157-560-01 | 62157 | - | |
| 62157-596-01 | 62157 | - | |
| 62157-927-01 | 62157 | - | |
| 62991-2736-1 | 62991 | - | |
| 62991-2736-2 | 62991 | - | |
| 62991-2736-3 | 62991 | - | |
| 62991-2736-4 | 62991 | - | |
| 62991-2736-5 | 62991 | - | |
| 63732-2018-4 | 63732 | - |
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
Every non-trivial field is expected to include provenance and update timestamps.
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
VETORYL® CAPSULES
RX
Trilostane
Capsule
• Oral
|
Dechra Veterinary Products LLC | NADA 141-291 | Approved | Jul 14, 2026 |
Data source: FDA Animal Drugs @ FDA (public search export).
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.
FDA page: Open in Animal Drugs @ FDA
Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.
Source: FDA Animal Drugs @ FDA • Reference
Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.
Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed.
Source: FDA openFDA • Reference
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Behavior.
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Dachshund - Miniature, Male, 14 year, 5.897 kilogram • Drug: MSK, Unassigned, Oral, Frequency: 12 per hour • Reactions: Seizure NOS, Obtunded, Twitching, Restlessness, Walking difficulty… • Outcome: Euthanized
Dog, ['Chihuahua', 'Dog (unknown)'], Male, 14 year, 5.1 kilogram • Drug: MSK, Capsule, Oral, Dose: 10 Milligram per animal, Frequency: 24 per hour • Reactions: Vomiting, Diarrhea • Outcome: Outcome Unknown
Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Male, 11 year, 7.5 kilogram • Drug: MSK, Capsule, Oral, Dose: 20 Milligram per animal, Frequency: 24 per hour • Reactions: Elevated serum alkaline phosphatase, Elevated alanine aminotransferase • Outcome: Outcome Unknown
Dog, Bulldog - French, Female, 7 year, 12.3 kilogram • Drug: MSK, Capsule, Oral, Dose: 30 Milligram per animal, Frequency: 24 per hour • Reactions: Skin lesion NOS, Skin hyperaemia, Folliculitis, Skin ulcer, Lack of efficacy (bacteria) - NOS • Outcome: Ongoing
Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Female, 12 year, 4.1 kilogram • Drug: MSK, Capsule, Oral, Dose: 10 Milligram per animal, Frequency: 12 per hour • Reactions: Diarrhea, Weight gain, Hair change, Behavioral disorder (unspecified) • Outcome: Outcome Unknown
Dog, ['Dog (other)', 'Dog (unknown)'], Male, 13 year, 7.3 kilogram • Drug: MSK, Capsule, Oral, Dose: 20 Milligram per animal, Frequency: 12 per hour • Reactions: Liver failure, Death • Outcome: Died
Dog, ['Beagle', 'Dog (unknown)'], Male, 12 year, 19.3 kilogram • Drug: MSK, Capsule, Oral, Dose: 60 Milligram per animal, Frequency: 24 per hour • Reactions: Adrenal gland disorder NOS • Outcome: Outcome Unknown
Dog, Terrier - Yorkshire, Male, 10 year, 3.1 kilogram • Drug: MSK, Capsule, Oral, Dose: 5 Milligram per animal, Frequency: 24 per hour • Reactions: High sodium-potassium ratio, Wart, Dermal cyst, Low sodium-potassium ratio, Hyperkalaemia… • Outcome: Outcome Unknown
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluids and corticosteroids is required.
Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.